Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases

This publication has 177 references indexed in Scilit:

• Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes
  British Journal of Pharmacology, 2012
• GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
  British Journal of Pharmacology, 2012
• The pharmacology of Adrenomedullin 2/Intermedin
  British Journal of Pharmacology, 2012
• Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates
  American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2010
• Central amylin acts as an adiposity signal to control body weight and energy expenditure
  Physiology & Behavior, 2010
• Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
  Hepatology, 2010
• Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy
  Obesity, 2009
• Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
  The Lancet, 2009
• Salmon calcitonin reduces food intake through changes in meal sizes in male rhesus monkeys
  American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
• Intermedin (adrenomedullin‐2): a novel counter‐regulatory peptide in the cardiovascular and renal systems
  British Journal of Pharmacology, 2008